John G Ullman & Associates Inc. grew its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 26.3% in the second quarter, Holdings Channel reports. The fund owned 311,225 shares of the pharmaceutical company’s stock after acquiring an additional 64,725 shares during the quarter. GlaxoSmithKline accounts for about 2.2% of John G Ullman & Associates Inc.’s portfolio, making the stock its 11th largest position. John G Ullman & Associates Inc.’s holdings in GlaxoSmithKline were worth $12,455,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently added to or reduced their stakes in GSK. Norges Bank bought a new position in shares of GlaxoSmithKline during the 4th quarter valued at approximately $17,275,000. SG Americas Securities LLC boosted its holdings in GlaxoSmithKline by 405.9% in the 2nd quarter. SG Americas Securities LLC now owns 335,267 shares of the pharmaceutical company’s stock worth $13,417,000 after buying an additional 268,994 shares during the period. Schafer Cullen Capital Management Inc boosted its holdings in GlaxoSmithKline by 15.6% in the 2nd quarter. Schafer Cullen Capital Management Inc now owns 1,454,693 shares of the pharmaceutical company’s stock worth $58,799,000 after buying an additional 196,138 shares during the period. Foundry Partners LLC boosted its holdings in GlaxoSmithKline by 102.7% in the 2nd quarter. Foundry Partners LLC now owns 335,495 shares of the pharmaceutical company’s stock worth $13,427,000 after buying an additional 169,985 shares during the period. Finally, CIBC Asset Management Inc boosted its holdings in GlaxoSmithKline by 184.2% in the 1st quarter. CIBC Asset Management Inc now owns 232,295 shares of the pharmaceutical company’s stock worth $9,683,000 after buying an additional 150,545 shares during the period. 11.26% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Plc Glaxosmithkline bought 333,333 shares of the stock in a transaction on Monday, July 1st. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 10.00% of the company’s stock.
NYSE GSK traded up $0.23 on Friday, hitting $40.19. The stock had a trading volume of 1,366,700 shares, compared to its average volume of 2,473,920. GlaxoSmithKline plc has a 52-week low of $36.41 and a 52-week high of $42.47. The company has a debt-to-equity ratio of 7.86, a quick ratio of 0.48 and a current ratio of 0.71. The company has a market capitalization of $98.43 billion, a price-to-earnings ratio of 12.72, a price-to-earnings-growth ratio of 1.91 and a beta of 0.71. The firm has a 50-day moving average of $40.88 and a 200-day moving average of $40.47.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. The business had revenue of $10.04 billion for the quarter, compared to analysts’ expectations of $9.55 billion. As a group, research analysts anticipate that GlaxoSmithKline plc will post 2.94 earnings per share for the current fiscal year.
GSK has been the subject of several analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday. Cowen reaffirmed a “hold” rating and issued a $45.00 price objective on shares of GlaxoSmithKline in a report on Monday, June 10th. Morgan Stanley reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a report on Monday, June 17th. Finally, Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, April 25th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the company. GlaxoSmithKline currently has a consensus rating of “Hold” and an average target price of $42.66.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Convertible Shares
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.